BioCentury | May 2, 2005
Product Development

Unfinished business

...the technology to develop our own drugs." Thus, In January, Xsira changed its name from Norak Biosciences Inc....
BioCentury | Mar 14, 2005
Company News

Molecular Devices, Xsira Pharmaceuticals Inc. deal

...acquired the assets of Xsira's Transfluor imaging technology for $11 million in cash. Xsira (formerly Norak...
BioCentury | Nov 8, 2004
Company News

Norak, AstraZeneca deal

...Under a second license agreement, AZN will use Norak's Transfluor fluorescence-based GPCR technology to advance lead...
...GPCR technology to advance lead compounds discovered under the companies' 2002 high throughput screening deal. Norak Biosciences Inc....
BioCentury | Oct 25, 2004
Company News

Curis, Norak deal

...technology to develop cell lines expressing selected receptors from CRIS. Financial terms were not disclosed. Norak...
...the Transfluor technology from Duke University (Durham, N.C.) in 1999. Curis Inc. (CRIS), Cambridge, Mass. Norak Biosciences Inc....
BioCentury | Oct 18, 2004
Company News

Norak, Purdue Pharma deal

...develop cell lines that express a G protein-coupled receptor (GPCR) orphan target supplied by Purdue. Norak...
...lines, which it will use to screen Purdue's compound libraries. Financial terms were not disclosed. Norak Biosciences Inc....
BioCentury | Oct 13, 2004
Company News

Norak, Purdue GPCR deal

...technology to develop cell lines expressing an orphan GPCR target from Purdue Pharma (Stamford, Conn.). Norak...
BioCentury | Sep 13, 2004
Company News

Norak, Roche deal

...The companies extended for a second year their 2002 deal under which Norak provides ROCZ with...
...with its Transfluor cell lines expressing GPCR targets of interest (see BioCentury, Oct. 7, 2002). Norak Biosciences Inc....
BioCentury | Aug 16, 2004
Company News

Norak, BASF deal

...Norak will receive technology access and screening fees, and is eligible for milestones and royalties. Norak Biosciences Inc....
BioCentury | Aug 16, 2004
Company News

Norak, Lundbeck deal

...screen another of its GPCR targets using Norak's Transfluor technology (see BioCentury, Jan. 13, 2003). Norak...
...and use its high throughput imaging technology to screen the target against LUN's compound library. Norak Biosciences Inc....
BioCentury | Aug 11, 2004
Company News

Norak, BASF agbio deal

...portion of its compound library against GPCR targets from BASF to develop crop protection products. Norak...
Items per page:
1 - 10 of 49
BioCentury | May 2, 2005
Product Development

Unfinished business

...the technology to develop our own drugs." Thus, In January, Xsira changed its name from Norak Biosciences Inc....
BioCentury | Mar 14, 2005
Company News

Molecular Devices, Xsira Pharmaceuticals Inc. deal

...acquired the assets of Xsira's Transfluor imaging technology for $11 million in cash. Xsira (formerly Norak...
BioCentury | Nov 8, 2004
Company News

Norak, AstraZeneca deal

...Under a second license agreement, AZN will use Norak's Transfluor fluorescence-based GPCR technology to advance lead...
...GPCR technology to advance lead compounds discovered under the companies' 2002 high throughput screening deal. Norak Biosciences Inc....
BioCentury | Oct 25, 2004
Company News

Curis, Norak deal

...technology to develop cell lines expressing selected receptors from CRIS. Financial terms were not disclosed. Norak...
...the Transfluor technology from Duke University (Durham, N.C.) in 1999. Curis Inc. (CRIS), Cambridge, Mass. Norak Biosciences Inc....
BioCentury | Oct 18, 2004
Company News

Norak, Purdue Pharma deal

...develop cell lines that express a G protein-coupled receptor (GPCR) orphan target supplied by Purdue. Norak...
...lines, which it will use to screen Purdue's compound libraries. Financial terms were not disclosed. Norak Biosciences Inc....
BioCentury | Oct 13, 2004
Company News

Norak, Purdue GPCR deal

...technology to develop cell lines expressing an orphan GPCR target from Purdue Pharma (Stamford, Conn.). Norak...
BioCentury | Sep 13, 2004
Company News

Norak, Roche deal

...The companies extended for a second year their 2002 deal under which Norak provides ROCZ with...
...with its Transfluor cell lines expressing GPCR targets of interest (see BioCentury, Oct. 7, 2002). Norak Biosciences Inc....
BioCentury | Aug 16, 2004
Company News

Norak, BASF deal

...Norak will receive technology access and screening fees, and is eligible for milestones and royalties. Norak Biosciences Inc....
BioCentury | Aug 16, 2004
Company News

Norak, Lundbeck deal

...screen another of its GPCR targets using Norak's Transfluor technology (see BioCentury, Jan. 13, 2003). Norak...
...and use its high throughput imaging technology to screen the target against LUN's compound library. Norak Biosciences Inc....
BioCentury | Aug 11, 2004
Company News

Norak, BASF agbio deal

...portion of its compound library against GPCR targets from BASF to develop crop protection products. Norak...
Items per page:
1 - 10 of 49